What is the Fiscal Year for Janux Therapeutics?
Date: November 13, 2026
Janux Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
San Diego, California
Industry
Biotechnology Research
Stock Symbol
JANX
Website
https://januxrx.comDescription
Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. Janux is using its platform masking technology to engineer novel drug candidates that are designed to overcome the traditional T cell engager toxicity and efficacy limitations. Janux is proud to have earned a 𝐆𝐫𝐞𝐚𝐭 𝐏𝐥𝐚𝐜𝐞 𝐓𝐨 𝐖𝐨𝐫𝐤 𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧™ in 2024.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Janux Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.